# A First in Human Trial to Assess the Safety and Immunogenicity of LTB-SA7 Vaccine Against Staphylococcus Aureus.

> **NCT06719219** · PHASE1 · COMPLETED · sponsor: **LimmaTech Biologics AG** · enrollment: 129 (actual)

## Conditions studied

- Staphylococcus (S.) Aureus Infection

## Interventions

- **BIOLOGICAL:** LTB-SA7
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT06719219
- **Lead sponsor:** LimmaTech Biologics AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-01-07
- **Primary completion:** 2026-03-04
- **Final completion:** 2026-03-04
- **Target enrollment:** 129 (ACTUAL)
- **Last updated:** 2026-03-19

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06719219

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06719219, "A First in Human Trial to Assess the Safety and Immunogenicity of LTB-SA7 Vaccine Against Staphylococcus Aureus.". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06719219. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*